FDA OKs Subcutaneous Therapy for CIDP

HyQvia, which combines immunoglobulin with hyaluronidase, is administered subcutaneously by a healthcare professional or the patient or caregiver, after appropriate training.

Related Keywords

Elisa Butler ,Drug Administration ,Foundation International ,Immune Globulin Infusion ,Recombinant Human Hyaluronidase ,Inflammatory Neuropathy Cause ,Chronic Inflammatory Demyelinating Polyradiculoneuropathy ,Chronic Inflammatory Demyelinating Polyneuropathy ,Idp ,Caregiver ,Demyelination ,Emyelinating ,Riga ,Immunoglobulin A ,Intravenous Immunoglobulin ,Spain ,Pain Management ,Abdominal Pain ,Disability ,Back Pain ,Fatigue ,Prabdominal ,Fever ,Pyrexia ,Ebrile Response ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,